Overview

A Study of ND0801 in Attention Deficit/Hyperactivity Disorder (ADHD)

Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
A multicenter, open label, escalating dose study to assess the tolerability and the safety and to explore the efficacy and the pharmacokinetics of ND0801 in adult patients with attention deficit/hyperactivity disorder (ADHD).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
NeuroDerm Ltd.